Compare Liberty Global Ltd Class C (LBTYK) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Sana Biotechnology Inc — how do they compare? Liberty Global Ltd Class C trades at $10.11 (market cap $3.48B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Liberty Global Ltd Class C is far larger — about 3.1× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| LBTYK | SANA | |
|---|---|---|
Market Cap | $3.48B | $1.13B |
Sector | Technology | Health |
52-Week High | $12.67 | $5.92 |
52-Week Low | $9.59 | $2.68 |
Enterprise Value | $10.13B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $10.105, up 1.15% on the day, but technical indicators signal a bearish trend. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q2 2026 miss, while full-year 2025 showed a net loss of $7.14B. Positive cash flow of $264.80M in 2025 and strategic moves like the Ziggo Group spin-off planned for 2027 highlight management's focus on unlocking value. Analyst sentiment is largely bullish with 69% buy ratings, citing sum-of-the-parts potential.
The outlook hinges on execution of asset monetizations and the Ziggo listing, offering upside if successful, but persistent losses and competitive pressures pose risks. Investors should weigh the high analyst optimism against fundamental weaknesses and market volatility.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
